Belinostat, at Its Clinically Relevant Concentrations, Inhibits Rifampicin-Induced CYP3A4 and MDR1 Gene Expression

Kodye L. Abbott, Chloe S. Chaudhury, Aneesh Chandran, Saraswathi Vishveshwara, Zdenek Dvorak, Eva Jiskrova, Karolina Poulikova, Barbora Vyhlidalova, Sridhar Mani, Satyanarayana R. Pondugula

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Activation of human pregnane X receptor (hPXR) has been associated with induction of chemoresistance. It has been proposed that such chemoresistance via cytochrome P450/drug transporters can be reversed with the use of antagonists that specifically abrogate agonist-mediated hPXR activation. Unfortunately, proposed antagonists lack the specificity and appropriate pharmacological characteristics that allow these features to be active in the clinic. We propose that, ideally, an hPXR antagonist would be a cancer drug itself that is part of a "cancer drug cocktail" and effective as an hPXR antagonist at therapeutic concentrations. Belinostat (BEL), a histone deacetylase inhibitor approved for the treatment of relapsed/refractory peripheral T-cell lymphoma, and often used in combination with chemotherapy, is an attractive candidate based on its hPXR ligand-like features. We sought to determine whether these features of BEL might allow it to behave as an antagonist in combination chemotherapy regimens that include hPXR activators. BEL represses agonist-activated hPXR target gene expression at its therapeutic concentrations in human primary hepatocytes and LS174T human colon cancer cells. BEL repressed rifampicin-induced gene expression of CYP3A4 and multidrug resistance protein 1, as well as their respective protein activities. BEL decreased rifampicin-induced resistance to SN-38, the active metabolite of irinotecan, in LS174T cells. This finding indicates that BEL could suppress hPXR agonist-induced chemoresistance. BEL attenuated the agonist-induced steroid receptor coactivator-1 interaction with hPXR, and, together with molecular docking studies, the study suggests that BEL directly interacts with multiple sites on hPXR. Taken together, our results suggest that BEL, at its clinically relevant therapeutic concentration, can antagonize hPXR agonist-induced gene expression and chemoresistance.

Original languageEnglish (US)
Pages (from-to)324-334
Number of pages11
JournalMolecular Pharmacology
Volume95
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Cytochrome P-450 CYP3A
Rifampin
Gene Expression
irinotecan
Combination Drug Therapy
belinostat
pregnane X receptor
Nuclear Receptor Coactivator 1
Pharmaceutical Preparations
Peripheral T-Cell Lymphoma
Histone Deacetylase Inhibitors
P-Glycoprotein
Therapeutics
Colonic Neoplasms
Cytochrome P-450 Enzyme System
Hepatocytes
Neoplasms

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Abbott, K. L., Chaudhury, C. S., Chandran, A., Vishveshwara, S., Dvorak, Z., Jiskrova, E., ... Pondugula, S. R. (2019). Belinostat, at Its Clinically Relevant Concentrations, Inhibits Rifampicin-Induced CYP3A4 and MDR1 Gene Expression. Molecular Pharmacology, 95(3), 324-334. https://doi.org/10.1124/mol.118.114587

Belinostat, at Its Clinically Relevant Concentrations, Inhibits Rifampicin-Induced CYP3A4 and MDR1 Gene Expression. / Abbott, Kodye L.; Chaudhury, Chloe S.; Chandran, Aneesh; Vishveshwara, Saraswathi; Dvorak, Zdenek; Jiskrova, Eva; Poulikova, Karolina; Vyhlidalova, Barbora; Mani, Sridhar; Pondugula, Satyanarayana R.

In: Molecular Pharmacology, Vol. 95, No. 3, 01.03.2019, p. 324-334.

Research output: Contribution to journalArticle

Abbott, KL, Chaudhury, CS, Chandran, A, Vishveshwara, S, Dvorak, Z, Jiskrova, E, Poulikova, K, Vyhlidalova, B, Mani, S & Pondugula, SR 2019, 'Belinostat, at Its Clinically Relevant Concentrations, Inhibits Rifampicin-Induced CYP3A4 and MDR1 Gene Expression', Molecular Pharmacology, vol. 95, no. 3, pp. 324-334. https://doi.org/10.1124/mol.118.114587
Abbott, Kodye L. ; Chaudhury, Chloe S. ; Chandran, Aneesh ; Vishveshwara, Saraswathi ; Dvorak, Zdenek ; Jiskrova, Eva ; Poulikova, Karolina ; Vyhlidalova, Barbora ; Mani, Sridhar ; Pondugula, Satyanarayana R. / Belinostat, at Its Clinically Relevant Concentrations, Inhibits Rifampicin-Induced CYP3A4 and MDR1 Gene Expression. In: Molecular Pharmacology. 2019 ; Vol. 95, No. 3. pp. 324-334.
@article{0d09b6a419404fafbeb5eb96735ca134,
title = "Belinostat, at Its Clinically Relevant Concentrations, Inhibits Rifampicin-Induced CYP3A4 and MDR1 Gene Expression",
abstract = "Activation of human pregnane X receptor (hPXR) has been associated with induction of chemoresistance. It has been proposed that such chemoresistance via cytochrome P450/drug transporters can be reversed with the use of antagonists that specifically abrogate agonist-mediated hPXR activation. Unfortunately, proposed antagonists lack the specificity and appropriate pharmacological characteristics that allow these features to be active in the clinic. We propose that, ideally, an hPXR antagonist would be a cancer drug itself that is part of a {"}cancer drug cocktail{"} and effective as an hPXR antagonist at therapeutic concentrations. Belinostat (BEL), a histone deacetylase inhibitor approved for the treatment of relapsed/refractory peripheral T-cell lymphoma, and often used in combination with chemotherapy, is an attractive candidate based on its hPXR ligand-like features. We sought to determine whether these features of BEL might allow it to behave as an antagonist in combination chemotherapy regimens that include hPXR activators. BEL represses agonist-activated hPXR target gene expression at its therapeutic concentrations in human primary hepatocytes and LS174T human colon cancer cells. BEL repressed rifampicin-induced gene expression of CYP3A4 and multidrug resistance protein 1, as well as their respective protein activities. BEL decreased rifampicin-induced resistance to SN-38, the active metabolite of irinotecan, in LS174T cells. This finding indicates that BEL could suppress hPXR agonist-induced chemoresistance. BEL attenuated the agonist-induced steroid receptor coactivator-1 interaction with hPXR, and, together with molecular docking studies, the study suggests that BEL directly interacts with multiple sites on hPXR. Taken together, our results suggest that BEL, at its clinically relevant therapeutic concentration, can antagonize hPXR agonist-induced gene expression and chemoresistance.",
author = "Abbott, {Kodye L.} and Chaudhury, {Chloe S.} and Aneesh Chandran and Saraswathi Vishveshwara and Zdenek Dvorak and Eva Jiskrova and Karolina Poulikova and Barbora Vyhlidalova and Sridhar Mani and Pondugula, {Satyanarayana R.}",
year = "2019",
month = "3",
day = "1",
doi = "10.1124/mol.118.114587",
language = "English (US)",
volume = "95",
pages = "324--334",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Belinostat, at Its Clinically Relevant Concentrations, Inhibits Rifampicin-Induced CYP3A4 and MDR1 Gene Expression

AU - Abbott, Kodye L.

AU - Chaudhury, Chloe S.

AU - Chandran, Aneesh

AU - Vishveshwara, Saraswathi

AU - Dvorak, Zdenek

AU - Jiskrova, Eva

AU - Poulikova, Karolina

AU - Vyhlidalova, Barbora

AU - Mani, Sridhar

AU - Pondugula, Satyanarayana R.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Activation of human pregnane X receptor (hPXR) has been associated with induction of chemoresistance. It has been proposed that such chemoresistance via cytochrome P450/drug transporters can be reversed with the use of antagonists that specifically abrogate agonist-mediated hPXR activation. Unfortunately, proposed antagonists lack the specificity and appropriate pharmacological characteristics that allow these features to be active in the clinic. We propose that, ideally, an hPXR antagonist would be a cancer drug itself that is part of a "cancer drug cocktail" and effective as an hPXR antagonist at therapeutic concentrations. Belinostat (BEL), a histone deacetylase inhibitor approved for the treatment of relapsed/refractory peripheral T-cell lymphoma, and often used in combination with chemotherapy, is an attractive candidate based on its hPXR ligand-like features. We sought to determine whether these features of BEL might allow it to behave as an antagonist in combination chemotherapy regimens that include hPXR activators. BEL represses agonist-activated hPXR target gene expression at its therapeutic concentrations in human primary hepatocytes and LS174T human colon cancer cells. BEL repressed rifampicin-induced gene expression of CYP3A4 and multidrug resistance protein 1, as well as their respective protein activities. BEL decreased rifampicin-induced resistance to SN-38, the active metabolite of irinotecan, in LS174T cells. This finding indicates that BEL could suppress hPXR agonist-induced chemoresistance. BEL attenuated the agonist-induced steroid receptor coactivator-1 interaction with hPXR, and, together with molecular docking studies, the study suggests that BEL directly interacts with multiple sites on hPXR. Taken together, our results suggest that BEL, at its clinically relevant therapeutic concentration, can antagonize hPXR agonist-induced gene expression and chemoresistance.

AB - Activation of human pregnane X receptor (hPXR) has been associated with induction of chemoresistance. It has been proposed that such chemoresistance via cytochrome P450/drug transporters can be reversed with the use of antagonists that specifically abrogate agonist-mediated hPXR activation. Unfortunately, proposed antagonists lack the specificity and appropriate pharmacological characteristics that allow these features to be active in the clinic. We propose that, ideally, an hPXR antagonist would be a cancer drug itself that is part of a "cancer drug cocktail" and effective as an hPXR antagonist at therapeutic concentrations. Belinostat (BEL), a histone deacetylase inhibitor approved for the treatment of relapsed/refractory peripheral T-cell lymphoma, and often used in combination with chemotherapy, is an attractive candidate based on its hPXR ligand-like features. We sought to determine whether these features of BEL might allow it to behave as an antagonist in combination chemotherapy regimens that include hPXR activators. BEL represses agonist-activated hPXR target gene expression at its therapeutic concentrations in human primary hepatocytes and LS174T human colon cancer cells. BEL repressed rifampicin-induced gene expression of CYP3A4 and multidrug resistance protein 1, as well as their respective protein activities. BEL decreased rifampicin-induced resistance to SN-38, the active metabolite of irinotecan, in LS174T cells. This finding indicates that BEL could suppress hPXR agonist-induced chemoresistance. BEL attenuated the agonist-induced steroid receptor coactivator-1 interaction with hPXR, and, together with molecular docking studies, the study suggests that BEL directly interacts with multiple sites on hPXR. Taken together, our results suggest that BEL, at its clinically relevant therapeutic concentration, can antagonize hPXR agonist-induced gene expression and chemoresistance.

UR - http://www.scopus.com/inward/record.url?scp=85060938227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060938227&partnerID=8YFLogxK

U2 - 10.1124/mol.118.114587

DO - 10.1124/mol.118.114587

M3 - Article

C2 - 30622215

AN - SCOPUS:85060938227

VL - 95

SP - 324

EP - 334

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 3

ER -